Get the Stockscreener App
366.21
0.43%
-1.58
After Hours:
366.21
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $366.21, with a volume of 1.49M.
It is down -0.43% in the last 24 hours and down -0.81% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$367.79
Open:
$370.68
24h Volume:
1.49M
Relative Volume:
0.54
Market Cap:
$197.41B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
25.73
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-0.90%
1M Performance:
-0.81%
6M Performance:
+32.50%
1Y Performance:
+17.13%
1-Day Range:
$365.93
$372.98
1-Week Range:
$365.93
$380.14
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
366.21 | 198.26B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
985.08 | 872.68B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 583.29B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 398.49B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 298.53B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 294.33B | 54.72B | 14.02B | 15.32B | 7.1855 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar - Law360
Amgen Inc. Stock (ISIN: US0311621009) Hits Defensive Strength Amid Biotech Shifts - AD HOC NEWS
Starbucks, Amgen, CVS and Other Stocks Help This Income Fund Shine - Barron's
Amgen vs Sanofi – A chronology of the patent battle over Repatha and Praluent - JUVE Patent
Amgen Inc. $AMGN Shares Sold by Martingale Asset Management L P - MarketBeat
Invesco Ltd. Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Mackenzie Financial Corp - MarketBeat
Amgen Inc. $AMGN Shares Bought by American Investment Services Inc. - MarketBeat
Advisory Research Inc. Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen and Sanofi end epic battle over Praluent and Repatha - JUVE Patent
Is It Time To Reassess Amgen (AMGN) After Its Strong 1 Year Share Price Run? - simplywall.st
Amgen: MariTide And Osteoporosis Sales Fuel The Rally (NASDAQ:AMGN) - Seeking Alpha
SevenBridge Financial Group LLC Decreases Position in Amgen Inc. $AMGN - MarketBeat
Franklin Resources Inc. Lowers Position in Amgen Inc. $AMGN - MarketBeat
Inceptionr LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
Amgen Touts 2025 Double-Digit Growth, MariTide Obesity Push and BiTE Momentum at Leerink Conference - Yahoo Finance
Kepler Cheuvreux Suisse SA Makes New $5 Million Investment in Amgen Inc. $AMGN - MarketBeat
Anti Oral Mucositis Drug Market Is Booming So Rapidly | Amgen • Merck & Co. Inc. • Bristol-Myers Squibb - openPR.com
Amgen Inc. $AMGN Stock Holdings Decreased by Richard Bernstein Advisors LLC - MarketBeat
Amgen Inc. $AMGN Shares Bought by Russell Investments Group Ltd. - MarketBeat
Bank of Montreal Can Raises Stake in Amgen Inc. $AMGN - MarketBeat
Amgen further shrinking Montgomery County footprint, cutting 22 positions - The Business Journals
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained - AOL.com
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained - 24/7 Wall St.
Forecasting The Future: 15 Analyst Projections For Amgen - Benzinga
Van ECK Associates Corp Purchases 567,400 Shares of Amgen Inc. $AMGN - MarketBeat
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe's, Qualcomm, Rivian, Strategy and More - 24/7 Wall St.
Amgen Inc. $AMGN Stock Holdings Lifted by Capital Research Global Investors - MarketBeat
Capital International Ltd. CA Has $15.75 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Capital World Investors Acquires 1,935,876 Shares of Amgen Inc. $AMGN - MarketBeat
Capital International Sarl Purchases 46,052 Shares of Amgen Inc. $AMGN - MarketBeat
Capital International Investors Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Capital International Inc. CA Increases Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Holdings Boosted by Legal & General Group Plc - MarketBeat
Capital Group Investment Management PTE. LTD. Raises Stock Position in Amgen Inc. $AMGN - MarketBeat
Capital Group Private Client Services Inc. Decreases Position in Amgen Inc. $AMGN - MarketBeat
Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns - Yahoo Finance
Amgen Inc. $AMGN Shares Purchased by Schroder Investment Management Group - MarketBeat
Amgen Inc.: Close to a key resistance level - marketscreener.com
Crysvita Market Is Going to Boom | Kyowa Kirin • Amgen • Sanofi • Takeda Pharmaceutical - openPR.com
Rep. David Taylor Sells Off Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
SNL mocks Amgen’s Otezla in bizarre sketch featuring Ryan Gosling - Medical Marketing and Media
Amgen Named to Forbes’ 2026 List of America’s Best Large Employers - Amgen
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus - Yahoo Finance
Swiss National Bank Sells 77,600 Shares of Amgen Inc. $AMGN - MarketBeat
The first KRAS drugs have been sluggish on the market. Will the next generation fare better? - PharmaVoice
Therapeutics Companies Exceed Q4 2025 Revenue Estimates, Led by Novavax and AmgenNews and Statistics - IndexBox
Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
First Trust Advisors LP Sells 46,048 Shares of Amgen Inc. $AMGN - MarketBeat
Better Weight Loss Stock: Novo Nordisk Vs. Amgen - The Globe and Mail
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):